A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
=== Isotope ratio as tracer for fingerprint === In many areas of study the origin of a chemical or group of chemicals is of central importance. Questions such as the source of environmental pollutants, the origin of hormones in an athlete's body, or the authenticity of foods and flavorings are all examples where chemical compounds need to be identified and sourced. Hydrogen isotopes have found uses in these and many other diverse areas of study. Since many processes can affect the DHR of a given compound this ratio can be a diagnostic signature for compounds produced in a specific location or via a certain process. Once the DHRs of a number of sources are known the measurement of this ratio for a sample of unknown origin can often be used to link it back to a certain source or production method.
While roughly 400 public buildings in Ontario contain RAAC, the Science Centre is currently the only one in the province closed due to these concerns. The Ford government expedited its plan to relocate the Science Centre to the waterfront, targeting a 2028 opening, with a temporary location slated for January 2026. This drew further criticism, including from Moriyama Teshima Architects, the firm founded by the Science Centre's original architect. The architects offered to do pro bono design consulting services for the Government of Ontario to support immediate repairs to the roof, and called for other organizations to join the effort to facilitate repairs. Private donors, including Geoffrey Hinton, offered up to $1 million to fund repairs for the existing facility, but the province did not respond to these offers. By October 31, 2024, most of the exhibits had been moved to storage facilities in northern Toronto and Guelph, while the animals and plants had been transferred to the Toronto Zoo and The Village at Black Creek. Temporary pop-up exhibits have since opened at Sherway Gardens and Toronto's Harbourfront Centre.
== Macrophage activated phenotypes == Macrophages inherently display tissue and environment-dependent plasticity. In addition, the phenotypes of the macrophages in a certain environment play a fundamental role in determining the immune activity and response within the tissue. Depending on the combination of MAFs signaling to the macrophage, the macrophage’s activated phenotype becomes one of three major categories: classically activated, wound healing, or regulatory. Regulatory-phenotype macrophages have only recently been recognized as an important contributor to tissue microenvironments. Tumor-associated macrophages may be any of these types, and they have been found to be important players in the tumor microenvironment. Analysis of the macrophage population and signaling in a tumor may provide useful clinical data.
Sources: en.wikipedia.org
A Komodo dragon may attempt to speed up the process by ramming the carcass against a tree to force it down its throat, sometimes ramming so forcefully that the tree is knocked down. A small tube under the tongue that connects to the lungs allows it to breathe while swallowing. After eating up to 80% of its body mass in one meal, it drags itself to a sunny location to speed digestion, as the food could rot and poison the dragon if left undigested in its stomach for too long. Because of their slow metabolism, large dragons can survive on as few as 12 meals a year. After digestion, the Komodo dragon regurgitates a mass of horns, hair, and teeth known as the gastric pellet, which is covered in malodorous mucus. After regurgitating the gastric pellet, it rubs its face in the dirt or on bushes to get rid of the mucus.
==== Ionic selectivity and plasticity ==== Several groups reinvestigated the permeability properties of TPCs and their role in NAADP-induced Ca2+ release, and they agreed that TPCs are indeed permeable to Na+ but they could not necessarily recapitulate the Na+ selectivity shown in the 2012/13 studies. It was therefore initially proposed that TPCs may conduct both Ca2+ and Na+ (analogous to the NMDA receptor of the plasma membrane). As more studies were published, why some groups observe a Na+ selectivity while others see a mixed Na+/Ca2+ permeability was unclear until the important realization that the TPC2 ionic selectivity wholly depended on the activating ligand. Currents activated by PI(3,5)P2 were predominantly carried by Na+ whereas NAADP-activated currents showed an eight-fold increase in the Ca2+ permeability. This conveniently explained the discrepancies between groups as well as revealing that TPC2 is extraordinarily plastic in operating in different conductance modalities. Since then, it appears that TPC2 can be synergistically activated by co-application of NAADP and PI(3,5)P2, although the molecular mechanisms are unclear. Therefore, TPC2 can operate as either a Ca2+ or Na+ channel, depending on whether NAADP or lipid activate it.
The hydrophobic effect can be quantified by measuring the partition coefficients of non-polar molecules between water and non-polar solvents. The partition coefficients can be transformed to free energy of transfer which includes enthalpic and entropic components, ΔG = ΔH - TΔS. These components are experimentally determined by calorimetry. The hydrophobic effect was found to be entropy-driven at room temperature because of the reduced mobility of water molecules in the solvation shell of the non-polar solute; however, the enthalpic component of transfer energy was found to be favorable, meaning it strengthened water-water hydrogen bonds in the solvation shell due to the reduced mobility of water molecules. At the higher temperature, when water molecules become more mobile, this energy gain decreases along with the entropic component. The hydrophobic effect depends on the temperature, which leads to "cold denaturation" of proteins. The hydrophobic effect can be calculated by comparing the free energy of solvation with bulk water. In this way, the hydrophobic effect not only can be localized but also decomposed into enthalpic and entropic contributions.
Mostly containing a +5 species, which was immediately assigned to dubnium, it also had a +4 species; based on that result, the team decided that additional chemical separation was needed. In 2005, the experiment was repeated, with the final product being hydroxide rather than nitrate precipitate, which was processed further in both Livermore (based on reverse phase chromatography) and Dubna (based on anion exchange chromatography). The +5 species was effectively isolated; dubnium appeared three times in tantalum-only fractions and never in niobium-only fractions. It was noted that these experiments were insufficient to draw conclusions about the general chemical profile of dubnium. In 2009, at the JAEA tandem accelerator in Japan, dubnium was processed in nitric and hydrofluoric acid solution, at concentrations where niobium forms NbOF−4 and tantalum forms TaF−6. Dubnium's behavior was close to that of niobium but not tantalum; it was thus deduced that dubnium formed DbOF−4. From the available information, it was concluded that dubnium often behaved like niobium, sometimes like protactinium, but rarely like tantalum. In 2021, the volatile heavy group 5 oxychlorides MOCl3 (M = Nb, Ta, Db) were experimentally studied at the JAEA tandem accelerator. The trend in volatilities was found to be NbOCl3 > TaOCl3 ≥ DbOCl3, so that dubnium behaves in line with periodic trends.
Sources: en.wikipedia.org
== Pharmacodynamics == Efgartigimod alfa as a drug is an antibody fragment that binds to the neonatal Fc receptor. When this binding happens, the IgG recycling process is blocked. The amount of circulating IgG decreases and therefore prevents the acetylcholine receptors from being degraded by the autoantibodies that are responsible for the myasthenia gravis.
=== Cell-free systems === E. coli cell lysate containing the cellular components required for transcription and translation are used in this in vitro method of protein production. The advantage of such system is that protein may be produced much faster than those produced in vivo since it does not require time to culture the cells, but it is also more expensive. Vectors used for E. coli expression can be used in this system although specifically designed vectors for this system are also available. Eukaryotic cell extracts may also be used in other cell-free systems, for example, the wheat germ cell-free expression systems. Mammalian cell-free systems have also been produced.
Type 1 diabetes, sometimes called "juvenile diabetes", is caused by destruction of the beta cells of the pancreas. The condition is also referred to as insulin-dependent diabetes, meaning exogenous insulin injections must replace the insulin the pancreas is no longer capable of producing for the body's needs. Type 1 is the most common form of diabetes in dogs and affects approximately 0.34% of dogs. Gestational diabetes can develop in dogs as well. It can be prevented by behavioral and dietary management. Diabetes insipidus, which has nothing to do with blood sugar, but is a condition of insufficient antidiuretic hormone or resistance to it, also exists in dogs.
Military Engineer Services (Urdu: ایم ای ایس, "MES") is an inter-service organization of the Ministry of Defence responsible primarily for engineering and construction services for the Pakistan Armed Forces, including the Army, Navy, Airforce and the Ministry of Defense Production. Furthermore, it is involved in complex construction projects including hospitals, buildings, workshops, roads etc.
== Oligomerization == Glutathione S-transferases form homodimers, but in eukaryotes can also form heterodimers of the A1 and A2 or YC1 and YC2 subunits. The homodimeric enzymes display a conserved structural fold. Each monomer is composed of a distinct N-terminal sub-domain, which adopts the thioredoxin fold, and a C-terminal all-helical sub-domain. This entry is the C-terminal domain.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.